These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 19729051

  • 1. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
    Mabrouk OS, Marti M, Salvadori S, Morari M.
    Neuroscience; 2009 Dec 01; 164(2):360-9. PubMed ID: 19729051
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
    Mabrouk OS, Volta M, Marti M, Morari M.
    J Neurochem; 2008 Dec 01; 107(6):1647-59. PubMed ID: 19094058
    [Abstract] [Full Text] [Related]

  • 3. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Marti M, Trapella C, Morari M.
    J Neurochem; 2008 Dec 01; 107(6):1683-96. PubMed ID: 19014386
    [Abstract] [Full Text] [Related]

  • 4. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
    Volta M, Viaro R, Trapella C, Marti M, Morari M.
    Exp Neurol; 2011 Mar 01; 228(1):126-37. PubMed ID: 21215744
    [Abstract] [Full Text] [Related]

  • 5. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
    Marti M, Trapella C, Viaro R, Morari M.
    J Neurosci; 2007 Feb 07; 27(6):1297-307. PubMed ID: 17287504
    [Abstract] [Full Text] [Related]

  • 6. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
    Yamamura S, Ohoyama K, Nagase H, Okada M.
    Neuropharmacology; 2009 Sep 07; 57(3):322-31. PubMed ID: 19482038
    [Abstract] [Full Text] [Related]

  • 7. Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist.
    Vergura R, Balboni G, Spagnolo B, Gavioli E, Lambert DG, McDonald J, Trapella C, Lazarus LH, Regoli D, Guerrini R, Salvadori S, Caló G.
    Peptides; 2008 Jan 07; 29(1):93-103. PubMed ID: 18069089
    [Abstract] [Full Text] [Related]

  • 8. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
    Mabrouk OS, Marti M, Morari M.
    Neuroscience; 2010 Mar 10; 166(1):40-8. PubMed ID: 20006677
    [Abstract] [Full Text] [Related]

  • 9. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
    Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M.
    J Neurosci; 2014 Sep 24; 34(39):12953-62. PubMed ID: 25253844
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
    Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pelà M, Trapella C, Morari M.
    Peptides; 2010 Jun 24; 31(6):1194-204. PubMed ID: 20307605
    [Abstract] [Full Text] [Related]

  • 11. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
    Fantin M, Auberson YP, Morari M.
    J Neurochem; 2008 Jul 24; 106(2):957-68. PubMed ID: 18435828
    [Abstract] [Full Text] [Related]

  • 12. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
    Ochi M, Shiozaki S, Kase H.
    Neuroscience; 2004 Jul 24; 127(1):223-31. PubMed ID: 15219684
    [Abstract] [Full Text] [Related]

  • 13. Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus.
    Windels F, Carcenac C, Poupard A, Savasta M.
    J Neurosci; 2005 May 18; 25(20):5079-86. PubMed ID: 15901790
    [Abstract] [Full Text] [Related]

  • 14. NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways.
    Fantin M, Marti M, Auberson YP, Morari M.
    J Neurochem; 2007 Dec 18; 103(6):2200-11. PubMed ID: 17986236
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.
    Korkmaz OT, Tunçel N, Tunçel M, Oncü EM, Sahintürk V, Celik M.
    J Mol Neurosci; 2010 Jun 18; 41(2):278-87. PubMed ID: 19953344
    [Abstract] [Full Text] [Related]

  • 16. Dopamine D4 receptor stimulation in GABAergic projections of the globus pallidus to the reticular thalamic nucleus and the substantia nigra reticulata of the rat decreases locomotor activity.
    Erlij D, Acosta-García J, Rojas-Márquez M, González-Hernández B, Escartín-Perez E, Aceves J, Florán B.
    Neuropharmacology; 2012 Feb 18; 62(2):1111-8. PubMed ID: 22108379
    [Abstract] [Full Text] [Related]

  • 17. Relative involvement of globus pallidus and subthalamic nucleus in the regulation of somatodendritic dopamine release in substantia nigra is dopamine-dependent.
    Cobb WS, Abercrombie ED.
    Neuroscience; 2003 Feb 18; 119(3):777-86. PubMed ID: 12809698
    [Abstract] [Full Text] [Related]

  • 18. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
    Marti M, Mela F, Guerrini R, Calò G, Bianchi C, Morari M.
    J Neurochem; 2004 Dec 18; 91(6):1501-4. PubMed ID: 15584926
    [Abstract] [Full Text] [Related]

  • 19. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain.
    Ferraro L, Tomasini MC, Fernandez M, Bebe BW, O'Connor WT, Fuxe K, Glennon JC, Tanganelli S, Antonelli T.
    Neuroscience; 2001 Dec 18; 102(1):113-20. PubMed ID: 11226674
    [Abstract] [Full Text] [Related]

  • 20. Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
    Ferraro L, O'Connor WT, Beggiato S, Tomasini MC, Fuxe K, Tanganelli S, Antonelli T.
    Eur J Neurosci; 2012 Jan 18; 35(2):207-20. PubMed ID: 22211865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.